Biofrontera SEC Filings

BFRIW NASDAQ

Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading Biofrontera’s SEC filings can feel like deciphering a clinical study—pages of FDA language, trial data, and device revenue details buried in fine print. Stock Titan’s AI-powered analysis turns those dense documents into plain-English insights in seconds.

Need the latest Biofrontera quarterly earnings report 10-Q filing or the full Biofrontera annual report 10-K simplified? We stream every form directly from EDGAR and tag the sections that matter—PDT sales trends, RhodoLED production costs, and R&D spend on next-gen dermatology therapies. Our platform also delivers real-time Biofrontera insider trading Form 4 transactions, so you can track executive stock moves before material events hit the tape.

Unsure where to locate FDA correspondence or clinical-trial milestones? The 8-K material events explained panel flags approvals, setbacks, and distribution agreements the moment Biofrontera files. Proxy statement executive compensation tables are condensed, letting you compare option grants with performance targets without scrolling through appendices.

With comprehensive coverage—from S-3 shelf registrations to detailed Biofrontera Form 4 insider transactions real-time alerts—Stock Titan equips analysts to:

Monitor segment revenue shifts between Ameluz gel and RhodoLED devices
Compare quarter-over-quarter gross margin trends quickly
Evaluate dilution risk via warrant and ATM issuance disclosures

No more digging through 300-page PDFs. Understanding Biofrontera SEC documents with AI means clear answers, faster decisions, and fewer surprises.

06/18/2025 04:15 PM

Filing

[8-K] Biofrontera Inc. Warrants Reports Material Event

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Biofrontera (BFRIW)?

The current stock price of Biofrontera (BFRIW) is $0.0899 as of June 26, 2025.

What is the core business of Biofrontera Inc.?

Biofrontera Inc. is a biopharmaceutical company focused on commercializing prescription therapies for dermatological conditions. It integrates pharmaceutical products with specialized light-based medical devices for photodynamic therapy.

How does Biofrontera generate revenue?

The company generates revenue primarily through the sales of its prescription drugs and complementary medical devices that are used together in photodynamic therapy, addressing conditions such as actinic keratosis and impetigo.

What is photodynamic therapy (PDT) and why is it significant for the company?

Photodynamic therapy involves using light-sensitive compounds activated by specific wavelengths of light to treat diseased cells. Biofrontera’s application of PDT in dermatology demonstrates its innovative approach to treating conditions like pre-cancerous lesions.

What types of skin conditions are addressed by Biofrontera's products?

The company’s products target conditions such as actinic keratosis, which are pre-cancerous skin lesions, and bacterial infections like impetigo. Their integrated approach enhances treatment efficacy in these challenging dermatological areas.

How does Biofrontera differentiate itself within the healthcare market?

Biofrontera differentiates itself by combining advanced pharmaceutical therapies with proprietary photodynamic therapy devices, allowing for a comprehensive treatment approach that addresses both chemical and procedural aspects of skin care management.

What role does research and development play at Biofrontera?

Research and development are central to Biofrontera’s strategy, enabling continuous improvement in therapeutic protocols and product efficacy. The company consistently invests in clinical research to uphold high standards in patient treatment and device safety.

What is the competitive landscape like for Biofrontera Inc.?

Biofrontera operates in a specialized segment of the biopharmaceutical industry where competition includes both pharmaceutical companies and medical device providers. Its unique integration of photodynamic therapy into dermatological treatments provides a competitive edge.

How do Biofrontera's products impact clinical outcomes?

The combination of prescription drugs with targeted photodynamic therapy devices enhances treatment outcomes by providing a dual approach to managing challenging skin conditions. This integrated method improves therapeutic effectiveness and patient quality of life.